ロード中...
Natalizumab and Progressive Multifocal Leukoencephalopathy: What are the causal factors? Can it be avoided?
Natalizumab (Tysabri®) was the first monoclonal antibody approved for the treatment of relapsing forms of multiple sclerosis (MS). After its initial approval, three patients undergoing natalizumab therapy in combination with other immunoregulatory and immunosuppressive agents were diagnosed with pro...
保存先:
| 主要な著者: | , , , , , , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2010
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4157908/ https://ncbi.nlm.nih.gov/pubmed/20697042 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/archneurol.2010.161 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|